China Sees Explosion Of R&D Outsourcing Business In Three Years
This article was originally published in PharmAsia News
In the three years since China began offering drug discovery and development services to foreign drug makers, the industry has become a world leader offering a wide range of services. The contract research industry in China was built in part by attracting skilled scientists and managers from Japan, the United States and other countries. A similar industry is expanding in India. China and India are taking advantage of a perceived need by Western drug makers to trim the average $1 billion cost of bringing new drugs to market. (Click here for more
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.